logo
calendar22 Oktabr 2019
view30
Main language:Russian

ASSESSMENT OF TOXICITY BY BIOLOGICALLY ACTIVE FOOD SUPPLEMENTS «DEFIZINC»

Field of Science:
pdf

20191022052753_Farmvest....pdf

PDF

Oʻzbekiston farmatsevtik xabarnomasi

Oʻzbekiston farmatsevtik xabarnomasi

Publish Articlesee more

ARTICLE ANNOTATION

quote
The company "Pharmaxx International" Ltd. (Uzbekistan) has developed a biologically active additive (BAA) for food "DefiZinc", which includes vitamin C and micronutrient - zinc. This dietary supplement is studied for acute and chronic toxicity. The experiments of acute toxicity of dietary supplements "DefiZinc" showed no symptoms of intoxication in animals. There were no animal deaths when rats have got per os BAA "DefiZinc" at doses of 2500, 5000 and 7500 mg/kg. The "DefiZinc" dietary supplements were given to rats for 30 days at doses of 40, 400 and 800 mg/kg and at the end of the experiment hematological and biochemical blood indices of the rats of the experimental and intact group were compared. As a result, no statistically significant differences were found. Examined BAD "DefiZinc" in terms of toxicity, can be attributed to class 4 - low-toxic substances.

AUTHORS

A.Raxmanov

Ташкентская медицинская академия

A.Abidova

Ташкентская медицинская академия

N.Seomashko

Ташкентская медицинская академия

L.Xegay

Ташкентская медицинская академия

Tags

# баҳолаш# «DefiZinc»# гематологические показатели# активность трансаминазных фермен# "DefiZinc"# hematological indices# activity of transaminase enzymes# биологик фаол қўшимча# токсиклик

OTHER ARTICLES IN THIS JOURNAL

Rate Article

0
0 ratings
5
4
3
2
1

Article Identifiers

ROI:

https://eroi.uz/11.0014/A1019-0046

DOI:

Not Available

References

1. Ступень Е.Г., Коваленко В.В., Артемук Е.Г. Биологически активные соединения. //Сбор. Статей универ. Студ. Науч-практ. Конф. – Брест, -2016, -С. 95.

2. Livingstone C. Zinc: physiology, deficiency, and parenteral nutrition.//NutrClinPract.- 2015. №3. –С. 371-382.

3. Wong CP, Rinaldi NA, Ho E. Zinc deficiency enhanced inflammatory response by increasing immune cell activation and inducing IL6 promoter demethylation.//MolNutr Food Res. -2015; -№59: -С. 991-999.

4. Higashi Y, Aratake T, Shimizu S, Shimizu T, Nakamura K, Tsuda M, Yawata T, Ueba T3 , Saito M. Influence of extracellular zinc on M1 microglial activation.//Sci Rep.-2017; №7: -С. 437-478.

5. Tarushi A, Kakoulidou C, Raptopoulou CP, Psycharis V, Kessissoglou DP, Zoi I, Papadopoulos AN, Psomas G. Zinc complexes of diflunisal: Synthesis, characterization, structure, antioxidant activity and in vitro and in silico study of the interaction with DNA and albumins.//J InorgBiochem.-2017; -№170: -С. 85-97.

6. Santucci NR, Alkhouri RH, Baker RD, Baker SS. Vitamin and zinc status pretreatment and posttreatment in patients with inflammatory bowel disease. //J. PediatrGastroenterolNutr-2014; -№59. –С. 455-457.

7. Weisshof R., Chermesh I. Micronutrient deficiencies in inflammatory bowel disease.//CurrOpinClinNutrMetab Care -2015; -№18. –С.576-581.

8. Жаворонкова A.M., Мугинова С.В., Шеховцова Т.Н. Определение микроколичеств цинка (II) по реактивации апоферментов щелочных фосфатаз различного происхождения//Журн. аналитхимии. -2003 -№6. -С.658-665.

9. Finney LA, O'Halloran TV. Transition metal speciation in the cell: insights from the chemistry of metal ion receptors.//Science. -2003. -№30. –С. 931–936.

10. Igic PG, Lee E, Harper W, Roach KW. Toxic effects associated with consumption of zinc.//Mayo Clin Proc.-2002.-№77. -С.713–716.

11. Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, et al. Elevated cortical zinc in Alzheimer disease. //Neurology. -2006. -№67. -С. 69–75.

12. Yokel RA. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration.//J Alzheimers Dis. -2006. -№10. -С.223–253.

13. Priel T, Aricha-Tamir B, Sekler I. Clioquinol attenuates zinc-dependent beta-cell death and the onset of insulitis and hyperglycemia associated with experimental type I diabetes in mice.//Eur J Pharmacol. -2007. - №565. -С. 232–239.

14. Хабриев Р.У. Методические указания по изучению общетоксического действия фармакологических веществ.//Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. М., 2005.